Pharmacogenomics of statins: understanding susceptibility to adverse effects

References

• IMS Institute for Healthcare InformaticsMedicines use and spending shifts: a review of the use of medicines in the U.S. in 2014Parsippany, NJIMS Institute for Healthcare Informatics2015
   Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomisedtrials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJLichtensteinAH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol201363252889293424239923
   PubMed Web of Science ®Google Scholar
• JacobsonTAItoMKMakiKCNational Lipid Association recommendations for patient-centered management of dyslipidemia. Part 1 – full reportJ Clin Lipidol20159212916925911072
   PubMed Web of Science ®Google Scholar
• StroesESThompsonPDCorsiniAStatin-associated muscle symptoms: impact on statin therapy–European Atherosclerosis Society consensus panel statement on assessment, aetiology and managementEur Heart J201536171012102225694464
   PubMed Web of Science ®Google Scholar
• LeusinkMOnland-MoretNCde BakkerPIde BoerAMaitland-van der ZeeAHSeventeen years of statin pharmacogenomics: a systematic reviewPharmacogenomics201617216318026670324
   PubMed Web of Science ®Google Scholar
• LawMRudnickaARStatin safety: a systematic reviewAm J Cardiol2006978A52C60C
   PubMed Web of Science ®Google Scholar
• ThompsonPDClarksonPKarasRHStatin-associated myopathyJAMA2003289131681169012672737
   PubMed Web of Science ®Google Scholar
• CohenJDBrintonEAItoMKJacobsonTAUnderstanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin usersJ Clin Lipidol20126320821522658145
   PubMed Web of Science ®Google Scholar
• BruckertEHayemGDejagerSYauCBégaudBMild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO studyCardiovasc Drugs Ther200519640341416453090
   PubMed Web of Science ®Google Scholar
• SimpsonRJMendysPThe effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic reviewJ Clin Lipidol20104646247121122692
   PubMed Web of Science ®Google Scholar
• The West of Scotland Coronary Prevention Study GroupCompliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention StudyEur Heart J19971811171817249402445
   PubMed Web of Science ®Google Scholar
• McGinnisBDOlsonKLDelateTMStolcpartRSStatin adherence and mortality in patients enrolled in a secondary prevention programAm J Manag Care2009151068969519845421
   PubMed Web of Science ®Google Scholar
• de DenusSSpinlerSAMillerKPetersonAMStatins and liver toxicity: a meta-analysisPharmacotherapy200424558459115162892
   PubMed Web of Science ®Google Scholar
• SuraweeraCde SilvaVHanwellaRSimvastatin-induced cognitive dysfunction: two case reportsJ Med Case Rep20161018327048383
   PubMedGoogle Scholar
• SallustioFStuderVTargeting new pharmacological approaches for Alzheimer’s disease: potential for statins and phosphodiesterase inhibitorsCNS Neurol Disord Drug Targets201615664765927189469
   PubMed Web of Science ®Google Scholar
• StulcTCeškaRGottoAMStatin intolerance: the clinicians’ perspectiveCurr Atheroscler Rep201517126926490078
   PubMed Web of Science ®Google Scholar
• NiemiMPasanenMKNeuvonePJOrganic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptakePharmacol Rev201163115718121245207
   PubMed Web of Science ®Google Scholar
• FengQWilkeRABayeTMIndividualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsPharmacogenomics201213557959422462750
   PubMed Web of Science ®Google Scholar
• LinkEParishSArmitageJSLCO1B1 variants and statin-induced myopathy–a genomewide studyN Engl J Med2008359878979918650507
   PubMed Web of Science ®Google Scholar
• PetersBJRodinASKlungelOHPharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarctionPharmacogenomics20101181065107620712525
   PubMed Web of Science ®Google Scholar
• YangGPYuanHTangBLack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patientsActa Pharmacol Sin201031338238620140004
   PubMed Web of Science ®Google Scholar
• DonnellyLADoneyASTavendaleRCommon nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS studyClin Pharmacol Ther201189221021621178985
   PubMed Web of Science ®Google Scholar
• BrunhamLRLansbergPJZhangLDifferential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatinPharmacogenomics J201212323323721243006
   PubMed Web of Science ®Google Scholar
• WilkeRARamseyLBJohnsonSGThe Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathyClin Pharmacol Ther201292111211722617227
   PubMed Web of Science ®Google Scholar
• RamseyLBJohnsonSGCaudleKEThe Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 updateClin Pharmacol Ther201496442342824918167
   PubMed Web of Science ®Google Scholar
• ManingatPGordonBRBreslowJLHow do we improve patient compliance and adherence to long-term statin therapy?Curr Atheroscle Rep2013151291
   PubMed Web of Science ®Google Scholar
• HagaSBLapointeNMThe potential impact of pharmacogenetic testing on medication adherencePharmacogenomics J201313648148323999596
   PubMed Web of Science ®Google Scholar
• JosephineLHJoySVHagaSBGenetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patientsJ Pers Med20144214716225563221
   PubMedGoogle Scholar
• KeskitaloJKurkinenKNeuvonenPNiemiMABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatinClin Pharmacol Ther200884445746119238649
   PubMed Web of Science ®Google Scholar
• FerrariMGuastiLMarescaAAssociation between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2Eur J Clin Pharmacol201470553954724595600
   PubMed Web of Science ®Google Scholar
• HoenigMRWalkerPJGurnseyCBeadleKJohnsonLThe C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohortJ Clin Lipidol201152919621392722
   PubMed Web of Science ®Google Scholar
• HermannMBogsrudMPMoldenEExposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathyClin Pharmacol Ther200679653253916765141
   PubMed Web of Science ®Google Scholar
• DeGorterMKTironaRGSchwarzUIClinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical careCirc Cardiovasc Genet20136440040823876492
   PubMed Web of Science ®Google Scholar
• FiegenbaumMda SilveiraFRvan der SandCRThe role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatmentClin Pharmacol Ther200578555155816321621
   PubMed Web of Science ®Google Scholar
• United States Federal Drug AdministrationFDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injuryUS FDA Safety Announcement 06–082011Washington DCFDA2011
   Google Scholar
• Whirl-CarrilloMMcDonaghEMHerbertJMPharmacgenomics knowledge for personalized medicineClin Pharmacol Ther201292441441722992668
   PubMed Web of Science ®Google Scholar
• WangDGuoYWrightonSACookeGESadeeWIntronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugsPharmacogenomics J201111427428620386561
   PubMed Web of Science ®Google Scholar
• ParkJEKimKBBaeSKMoonBSLiuKHShinJGContribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatinXenobiotica20083891240125118720283
   PubMed Web of Science ®Google Scholar
• Westlind-JohnssonAMalmeboSJohanssonAComparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolismDrug Metab Dispos200331675576112756208
   PubMed Web of Science ®Google Scholar
• TsamandourasNDickinsonGGuoYIdentification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approachClin Pharmacol Ther20149619010024598718
   PubMed Web of Science ®Google Scholar
• KimKAParkPWLeeOJKangDKParkJYEffect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjectsJ Clin Pharmacol2007471879317192506
   PubMed Web of Science ®Google Scholar
• KitzmillerJPLuzumJABaldassarreDKraussRMMedinaMWCYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohortPharmacogenet Genomics2014241048649125051018
   PubMed Web of Science ®Google Scholar
• ElensLBeckerMLHaufroidVNovel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam StudyPharmacogenet Genomics2011211286186621946898
   PubMed Web of Science ®Google Scholar
• KivistöKTNiemiMSchaeffelerELipid-lowering response to statins is affected by CYP3A5 polymorphismPharmacogenetics200414852352515284534
   PubMedGoogle Scholar
• RagiaGKolovouVTavridouANo effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemiaDrug Metab Pers Ther20153010434825274942
   PubMedGoogle Scholar
• HuMMakVWXiaoYTomlinsonBAssociations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemiaPharmacogenomics2013141253423252946
   PubMed Web of Science ®Google Scholar
• Whirl-CarrilloMMcDonaghEMHebertJMPharmacogenomics knowledge for personalized medicineClin Pharmacol Ther201292441441722992668
   PubMed Web of Science ®Google Scholar
• FreemanDJGriffinBAHolmesAPRegulation of plasma: associations between the TaqI B RFLP in the CETP gene and smoking and obesityArterioscler Thromb19941433363447907227
   PubMed Web of Science ®Google Scholar
• KuivenhovenJAJukemaJWZwindermanAHThe role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study GroupN Engl J Med1998338286939420339
   PubMed Web of Science ®Google Scholar
• Willer 2008Newly identified loci that influence lipid concentrations and risk of coronary artery diseaseNat Genet200840216116918193043
   PubMed Web of Science ®Google Scholar
• RegieliJJJukemaJWGrobbeeDECETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interactionEur Heart J200829222792279918957472
   PubMed Web of Science ®Google Scholar
• BoekholdtSMSacksFMJukemaJWCholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjectsCirculation2005111327828715655129
   PubMed Web of Science ®Google Scholar
• PappACPinsonneaultJKWangDCholesteryl ester transfer protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular riskPLoS One201273e3193022403620
   PubMed Web of Science ®Google Scholar
• KraussRMMangraviteLMSmithJDVariation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatmentCirculation2008117121537154418332269
   PubMed Web of Science ®Google Scholar
• ChasmanDIPosadaDSubrahmanyanLCookNRStantonVPJrRidkerPMPharmacogenetic study of statin therapy and cholesterol reductionJAMA2004291232821282715199031
   PubMed Web of Science ®Google Scholar
• SingerJBHoldaasHJardineAGGenetic analysis of fluvastatin response and dyslipidemia in renal transplant recipientsJ Lipid Res20074892072207817563401
   PubMed Web of Science ®Google Scholar
• DonnellyLADoneyASDannfaldJA paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS studyPharmacogenet Genomics200818121021102618815589
   PubMed Web of Science ®Google Scholar
• ThompsonJManMJohnsonKAn association study of 43 SNPs in 16 candidate genes with atorvastatin responsePharmacogenomics J20055635235816103896
   PubMed Web of Science ®Google Scholar
• PoliseckiEMuallemHMaedaNProspective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigators. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPERAtherosclerosis2008200110911418261733
   PubMed Web of Science ®Google Scholar
• ThompsonJFHydeCLWoodLSComprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohortCirc Cardiovasc Gen200922173181
   PubMed Web of Science ®Google Scholar
• PuccettiLCianiFAuteriAGenetic involvement in statins induced myopathy. Preliminary data from an observational case–control studyAtherosclerosis20102111282920347093
   PubMed Web of Science ®Google Scholar
• RuañoGWindemuthAWuAHBMechanisms of statin induced myalgia assessed by physiogenomic associationsAtherosclerosis2011218245145621868014
   PubMed Web of Science ®Google Scholar
• MarcoffLThompsonPDThe role of coenzyme Q10 in statin-associated myopathy: a systematic reviewJ Am Coll Cardiol200749232231223717560286
   PubMed Web of Science ®Google Scholar
• MangraviteLMEngelhardtBEMedinaMWA statin-dependent QTL for GATM expression is associated with statin-induced myopathyNature2013502747137738023995691
   PubMed Web of Science ®Google Scholar
• LuzumJAKitzmillerJPIsacksonPJGATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individualsCell Metab201521462262725863251
   PubMed Web of Science ®Google Scholar
• CarrDFAlfirevicAJohnsonRChinoyHvan StaaTPirmohamedMGATM gene variants and statin myopathy riskNature20145137518E1
   PubMed Web of Science ®Google Scholar
• FloydJSBisJCBrodyJAHeckbertSRRiceKPsatyBMGATM locus does not replicate in rhabdomyolysis studyNature20145137518E1E3
   PubMed Web of Science ®Google Scholar
• EdvardsonSKormanSHLivneAL-arginine:glycine amidinotransferase (AGAT) deficiency: clinical presentation and response to treatment in two patients with a novel mutationMol Genet Metab20101012–322823220682460
   PubMed Web of Science ®Google Scholar
• NouiouaSCheillanDZaouidiSCreatine deficiency syndrome. A treatable myopathy due to arginine-glycine amidinotransferase (AGAT) deficiencyNeuromuscul Disord201323867067423770102
   PubMed Web of Science ®Google Scholar
• Pharmacogenomics Knowledge Base (PharmGKB) and Stanford University Available from: https://www.pharmgkb.org/pathway/PA145011108Accessed September 20, 2016
   Google Scholar